Potentiation by acetylsalicylic acid of skin weal response to compound 48/80 in ASA-sensitive asthmatics.
The influence of acetylsalicylic acid (ASA) on skin response to intradermal injection of compound 48/80 and histamine was studied in order to determine whether ASA elicits any abnormalities also in the skin of asthmatics reacting with bronchoconstriction to ingestion of this drug. The applied ASA dose (mean dose 150 mg) elicited bronchoconstriction in all 16 patients with asthma and ASA sensitivity (mean fall of FEV1 34%) and increased the weal response to compound 48/80 to about 51% (P less than 0.05) as compared with the response before the ASA-challenge. In asthmatic persons without ASA sensitivity a 150 mg ASA dose did not influence the skin response to any of the reagents. On the other hand, a 600 mg dose decreased skin response to histamine and compound 48/80 in persons without ASA intolerance, although the decrease was statistically significant only in the flare after compound 48/80 (P less than 0.05). The authors believe that additional local defect is needed to reveal sensitivity to ASA in the skin of ASA-sensitive asthmatics, just as bronchial hyperreactivity is indispensible for revealing the action of ASA in the bronchi.
D000328:Adult; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology*; D001249:Asthma / Q000139:chemically induced*; D004357:Drug Synergism; D006632:Histamine / Q000008:administration & dosage; D006801:Humans; D007271:Injections, Intradermal; D012867:Skin / Q000187:drug effects*; D012882:Skin Tests; D003189:p-Methoxy-N-methylphenethylamine / Q000008:administration & dosage*
D003189:p-Methoxy-N-methylphenethylamine; D006632:Histamine; D001241:Aspirin